Characterisation of CYP102A25 from Bacillus marmarensis and CYP102A26 from Pontibacillus halophilus: P450 Homologues of BM3 with Preference towards Hydroxylation of Medium‐Chain Fatty Acids. (5th February 2018)

• Record Type: Journal Article
• Authors: Porter, Joanne L.; Manning, Jack; Sabatini, Selina; Tavanti, Michele; Turner, Nicholas J.; Flitsch, Sabine L.
• Is Part Of: Chembiochem. Volume 19:Number 5(2018)
• Page Start: 513
• Page End: 520
• Publication Date: 2018-02-05
• Subjects: biocatalysts -- cytochromes -- fatty acids -- hydroxylation -- myristic acid; Biochemistry -- Periodicals; Molecular biology -- Periodicals; Pharmaceutical chemistry -- Periodicals; 572
• DOI: 10.1002/cbic.201700598
• Languages: English
• ISSNs: 1439-4227

Abstract

Abstract: Cytochrome P450 monooxygenases are highly desired biocatalysts owing to their ability to catalyse a wide variety of chemically challenging C−H activation reactions. The CYP102A subfamily of enzymes are natural catalytically self‐sufficient proteins consisting of a haem and FMN‐FAD reductase domain fused in a single‐component system. They catalyse the oxygenation of saturated and unsaturated fatty acids to produce primarily ω−1, ω−2 and ω−3 hydroxy acids. These monooxygenases have potential applications in biotechnology; however, their substrate range is still limited and there is a continued need to add diversity to this class of biocatalysts. Herein, we present the characterisation of two new members of this class of enzymes, CYP102A25 (BMar) from Bacillus marmarensis and CYP102A26 (PHal) from Pontibacillus halophilus, both of which express readily in a recombinant bacterial host. BMar exhibits the highest activity toward myristic acid and shows moderate activity towards unsaturated fatty acids. PHal exhibits broader activity towards mid‐chain‐saturated (C14 –C18 ) and unsaturated fatty acids. Furthermore, PHal shows good regioselectivity for the hydroxylation of myristic acid, targeting the ω−2 position for C−H activation. Abstract : A new twist : Here new alternatives to the well‐studied prototype self‐sufficient CYP102A1 (P450 BM3) are presented. The new BM3 homologues, CYP102A25 (BMar) and CYP102A26 (PHal), have different substrate profiles encompassing saturated and unsaturated fatty acids. PHal also displays higher regioselectivity for the production of the ω−2 hydroxy acid than previously reported.